PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that the following clinical and preclinical
abstracts are expected to be the subject of oral or poster presentations at
the Annual Meeting of the American Association for Cancer Research (AACR),
being held April 12-16, 2008 in San Diego:
-- "Dendritic and T cell functions in patients with metastatic hormone-
refractory prostate cancer treated with GVAX immunotherapy for prostate
cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session)
- Oral presentation scheduled for Monday, April 14, 2008 at 1:25 p.m.
-- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent
induction of CD8+ T cell activation and clinical responses" (Abstract
#2539, Clinical Immunotherapy Session) - Oral presentation scheduled
for Monday, April 14, 2008 at 1:40 p.m.
-- "Increased doses of an anti-CD30 antibody, MDX-060, results in
prolonged progression free survival in subjects with CD30 positive
lymphoma" (Abstract #5525, Phase 2 and 3 Clinical Trials 3: Blood,
Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for
Wednesday, April 16, 2008 at 8:00 a.m.
-- "Preclinical development of anti B7-H4 therapeutic antibodies"
(Abstract #4986, Developmental Immunotherapy Session) - Oral
presentation scheduled for Tuesday, April 15, 2008 at 2:25 p.m.
-- "Human antibody conjugates of potential utility for prostate cancer
therapy: a comparison of MGBA conjugates with antibodies targeting a
cell surface target (prostate-specific membrane antigen) and an extra-
|SOURCE Medarex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved